Post-acute sequelae of SARS-CoV-2 infection (PASC) — commonly called Long COVID — affects an estimated 10–30% of people following acute COVID-19, representing what some researchers project to be 65 million people globally with persistent symptoms extending beyond 12 weeks post-infection. The condition's complexity — presenting heterogeneously across dozens of symptoms including fatigue, cognitive impairment ("brain fog"), post-exertional malaise, orthostatic intolerance, sleep disruption, and dysautonomia — initially confounded investigators, and the absence of objective biomarkers drove unfortunate skepticism about the condition's legitimacy. By 2025, the science has matured considerably: multiple converging lines of mechanistic evidence have been identified, and NIH-funded RECOVER Initiative clinical trials are testing targeted interventions for the first time.
Viral Reservoir Persistence
The most compelling mechanistic hypothesis is viral reservoir persistence — the presence of replication-competent SARS-CoV-2 RNA and protein in gastrointestinal tissue, lymph nodes, and the central nervous system months to years after acute infection. A landmark 2023 Nature study found SARS-CoV-2 spike protein detectable in blood monocytes of Long COVID patients up to 15 months after acute infection — absent in both fully recovered patients and those with persistent symptoms from other causes. Persistence in the gut lining correlates with ongoing immune activation. The RECOVER ACTIV trial is testing nirmatrelvir-ritonavir (Paxlovid) extended-course for 15 days in Long COVID patients — predicated on the hypothesis that antiviral therapy can clear the residual viral reservoir driving chronic immune stimulation.
Autoimmunity and Autoantibodies
Multiple research groups have identified autoantibodies in Long COVID patients — antibodies generated against SARS-CoV-2 that cross-react with host proteins, particularly autonomic nervous system receptors. Autoantibodies against β2-adrenergic receptors, muscarinic acetylcholine receptors, and angiotensin receptors have been identified at elevated frequencies in Long COVID patients compared to controls, providing a mechanistic explanation for the dysautonomia, POTS (postural orthostatic tachycardia syndrome), and heart rate variability abnormalities seen clinically. A small German trial using therapeutic plasma exchange (removing autoantibodies from circulation) demonstrated significant symptom improvement in a subset of Long COVID patients, warranting larger controlled trials.
Microbiome Disruption and Reactivation
Long COVID patients demonstrate persistent gut microbiome dysbiosis — reduced diversity and depletion of beneficial commensal bacteria including Faecalibacterium prausnitzii and Bifidobacterium longum — correlating with symptom severity and distinguishing Long COVID from fully recovered individuals. Concurrently, reactivation of latent herpesviruses — particularly Epstein-Barr virus (EBV) and HHV-6 — has been documented in Long COVID patients, mirroring the viral reactivation seen in other post-infectious fatigue syndromes. An FMT trial for Long COVID gut dysbiosis showed promising pilot results; valacyclovir (anti-herpetic) trials are underway.
Clinical Management in 2025
In the absence of approved targeted therapies, Long COVID management relies on evidence-based symptom treatment: POTS management (increased salt and fluid intake, compression garments, beta-blockers, fludrocortisone); post-exertional malaise management through pacing and graded activity within energy envelope; cognitive rehabilitation programs; sleep optimization; and multidisciplinary Long COVID clinics coordinating between immunology, cardiology, pulmonology, and neurology. Healthcare facilities providing Long COVID care need robust stocks of monitoring equipment for orthostatic vital sign assessments and patient care supplies supporting rehabilitation programs.
